UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000057985
Receipt number R000066286
Scientific Title Effects of consumption of the test food on cognitive function: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Date of disclosure of the study information 2025/05/27
Last modified on 2025/08/05 14:57:03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of consumption of the test food on cognitive function

Acronym

Effects of consumption of the test food on cognitive function

Scientific Title

Effects of consumption of the test food on cognitive function: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Scientific Title:Acronym

Effects of consumption of the test food on cognitive function

Region

Japan


Condition

Condition

Healthy Japanese

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the effects of 12 weeks of consumption of the test food on cognitive function in healthy Japanese men and women aged 40 or more, as well as to examine its secondary effects on blood levels of brain-derived neurotrophic factor (BDNF).

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. The measured value of standardized score for verbal memory on Cognitrax at 12 weeks after intervention (12w)

Key secondary outcomes

1. The measured value of raw score for verbal memory on Cognitrax at 12w

2. The measured values of standardized scores and raw scores for each cognitive domain (except for verbal memory) and each test result on Cognitrax at 12w

3. The measured value of BDNF at 12w


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Food

Interventions/Control_1

Duration: 12 weeks
Test product: Capsule containing scallop extract
Administration: Take two capsules per day with water before breakfast.

*If you forget to take the test food, take it as soon as you remember. The daily dose should be taken within the day and not carried over to the next day.

Interventions/Control_2

Duration: 12 weeks
Test product: Placebo food
Administration: Take two capsules per day with water before breakfast.

*If you forget to take the test food, take it as soon as you remember. The daily dose should be taken within the day and not carried over to the next day.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Individuals aged 40 or more

4. Healthy individuals

5. Individuals whose score of the Japanese version of the Mini Mental State Examination (MMSE-J) is 24 or more at screening

6. Individuals who have a "yes" in the validity indicator of verbal memory test on Cognitrax and the standardized score of verbal memory is less than 100 at screening

Key exclusion criteria

Individuals (who / whose)
1. are undergoing medical treatment or have a medical history of malignant tumor, heart failure, myocardial infarction, psychiatric disorder (including depressive symptoms), or cerebrovascular disease

2. have a pacemaker or an implantable cardioverter defibrillator (ICD)

3. are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases

4. have dementia

5. working pattern includes a late-night shift or early morning work

6. feel that their sleeping time are irregular

7. have a disability of both hands by injuries, surgeries, or other reasons

8. take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional foods/beverages

9. are taking or using medications (including herbal medicines) or supplements

10. take foods or supplements related to improving cognitive functions, such as docosahexaenoic acid, eicosapentaenoic acid, ginkgo leaf extract, tocotrienol, astaxanthin, gamma-aminobutyric acid, phosphatidylserine, or plasmalogen

11. take blue-backed fish such as sardines, mackerel, or saury at least four times a week

12. use devices, equipment, or applications that may affect cognitive functions (e.g., brain training puzzles or brain training games)

13. are allergic to medicines or foods related to the test product, particularly those who are allergic to shellfish or crustaceans such as shrimps and crabs

14. are pregnant, lactating, or planning to become pregnant during this study

15. have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study

16. are judged as ineligible to participate in this study by the physician

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

B&S corporation Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

B&S corporation Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2025 Year 05 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

68

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2025 Year 05 Month 12 Day

Date of IRB

2025 Year 05 Month 12 Day

Anticipated trial start date

2025 Year 05 Month 27 Day

Last follow-up date

2025 Year 10 Month 16 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2025 Year 05 Month 27 Day

Last modified on

2025 Year 08 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066286